On February 13, 2023 Caris Life Sciences(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, reported that the company and partners within the Caris Precision Oncology Alliance (POA) will collectively present five studies across three tumor types at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium, February 16-18, 2023 in San Francisco (Tabletop #50) (Press release, Caris Life Sciences, FEB 13, 2023, View Source [SID1234627130]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are proud of the growing number of collaborative abstracts accepted for presentation at ASCO (Free ASCO Whitepaper) GU, demonstrating the power of Caris’ comprehensive molecular profiling and the large-scale collaboration between POA sites," said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. "The findings represent important observations in prostate, urothelial, and renal cancers, which could lead to novel treatment strategies and knowledge that improve patient outcomes."

"At Caris, our goal is to enable clinicians to make the best treatment choices for their patients, researchers to discover new targets, and the biopharmaceutical industry to develop the next breakthrough medicines," said David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris. "These presentations show how our physicians, scientists and partners in the POA are leveraging real-world clinical evidence from over 455,000 lifetime cases in Caris’ unique AI-driven platform to deepen our understanding of cancer. These foundational discoveries provide key insights into advanced cancer and support the development of precision oncology approaches in advanced genitourinary tumors to better serve cancer patients."

Poster presentations include:

Clinical and Molecular Features of ATM and BRCA2 Mutations in Metastatic Prostate Cancer. (Poster Number: J8)
February 16, 11:30 AM – 1:00 PM PST
The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2/HER2 Expression. (Poster Number: M18)
February 17, 12:30 – 2:00 PM PST
Characterization and Impact of Wnt5A Signaling on Outcomes of Urothelial Carcinoma. (Poster Number: N3)
February 17, 12:30 – 2:00 PM PST
Exploration of Immunosuppressive Features of the Tumor Microenvironment within Hepatic and Non-Hepatic Tumors of Urothelial Origin. (Poster Number: N5)
February 17, 12:30 – 2:00 PM PST
Characterization of FOLH1 Expression in Renal Cell Carcinoma (RCC). (Poster Number: K8)
February 18, 7:00 – 8:00 AM PST
Poster and abstract summaries highlighting this research will be available onsite at Caris’ Tabletop #50. The full abstracts will be available through the official ASCO (Free ASCO Whitepaper) website February 13.

The Caris Precision Oncology Alliance includes 77 cancer centers and academic institutions in the United States and beyond. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic data available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma. Additionally, as a member of the POA, institutions have access to Caris CODEai, the most comprehensive data solution in the industry with cancer treatment information and real-world clinical outcomes evidence for over 350,000 patients covering over 1 million data points per patient.